A Randomized, Double-Blind, Placebo Controlled Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Subjects with Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

Protocol: 
AAAR1251
Phase: 
III

A Randomized, Double-Blind, Placebo Controlled Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Subjects with Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

The purpose of this study is to evaluate the efficacy (how well the study drug works) and safety of venetoclax in combination with azacitidine in subjects who have not been treated for their acute myeloid leukemia (AML). The tolerability of venetoclax will also be evaluated.

Are you Eligible? (Inclusion Criteria)

1) Subjects must be at least 60 years of age.

2) Subjects must have a confirmed diagnosis of AML.

3) Subjects must be in good physical shape. This means that subjects must be
able to walk, care for themselves, and do light physical activities such as
light housework or office work.

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States